Table 3 Efficacy.

From: Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients

Group

N

N (%)

ORRa

CBRb

sCR

CR

VGPRc

PR

MR

SD

Overall

32

25 (78.1)

26 (81.3)

2 (6.3)

3 (9.4)

9 (28.1)

11 (34.4)

1 (3.1)

6 (18.8)

Prior lines of therapy

   1–2

9

8 (88.9)

8 (88.9)

2 (22.2)

1 (11.1)

3 (33.3)

2 (22.2)

0 (0.0)

1 (11.1)

   ≥3

23

17 (73.9)

18 (78.3)

0 (0.0)

2 (8.7)

6 (26.1)

9 (39.1)

1 (4.3)

5 (21.7)

Triple-class status

   Not triple-class exposed

10

10 (100.0)

10 (100.0)

2 (20.0)

2 (20.0)

3 (30.0)

3 (30.0)

0 (0.0)

0 (0.0)

   Triple-class exposed

22

15 (68.2)

16 (72.7)

0 (0.0)

1 (4.5)

6 (27.3)

8 (36.4)

1 (4.5)

6 (27.3)

   Triple-class refractory

12

8 (66.7)

8 (66.7)

0 (0.0)

0 (0.0)

6 (50.0)

2 (16.7)

0 (0.0)

4 (33.3)

High-risk cytogeneticsd

         

   Yes

17

14 (82.4)

15 (88.2)

1 (5.9)

0 (0.0)

6 (35.3)

7 (41.2)

1 (5.9)

2 (11.8)

   No

15

11 (73.3)

11 (73.3)

1 (6.7)

3 (20.0)

3 (20.0)

4 (26.7)

0 (0.0)

4 (26.7)

  1. Note: Responses were investigator reported and internally assessed according to the International Myeloma Working Group criteria.
  2. CBR clinical benefit rate, MR minimal response, ORR overall response rate, PD progressive disease, PR partial response, SD stable disease, VGPR very good partial response.
  3. aOverall response rate is the proportion of patients who achieved a partial response or better, before disease progression or initiating a new MM treatment.
  4. bClinical benefit rate is the proportion of patients who achieved minimal response or better, before disease progression or initiating a new MM treatment.
  5. cOne very good partial response was unconfirmed.
  6. dDefined as any of del(17p), t(4;14), t(14;16), or gain 1q at initial diagnosis or screening.
Back to article page